We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Ian Walker
AstraZeneca PLC (AZN.LN) said Monday that it will take back the global rights to brazikumab after ending a license deal with Allergan PLC (AGN).
AstraZeneca said Allergen will fund the costs of developing brazikumab, which is used for Crohn's disease and ulcerative colitis.
The transaction is expected to complete in the first quarter of this year, subject to regulatory approvals associated with AbbVie Inc.'s (ABBV) proposed acquisition of Allergan, AstraZeneca said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 27, 2020 02:33 ET (07:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
